This article helps patients with GEP-NETs learn about lutetium Lu-177 dotatate (PRRT), a type of targeted radiation therapy they may consider.
Your pathology report has key numbers that help show whether PRRT may work for your neuroendocrine tumor. Three things on that report matter most: your tumor grade, your Ki-67 index, and whether your tumor cells are called well-differentiated or poorly-differentiated. Learning these terms helps you ask better questions at your next appointment and helps your team talk about treatment options you haven't discussed yet.
In short: well-differentiated GEP-NETs with a Ki-67 index of 20 percent or lower respond best to PRRT. But grade alone doesn't determine whether you're eligible. Somatostatin receptor expression - confirmed by a Ga-68 DOTATATE PET/CT scan - is the final requirement. Keep reading to understand why, and what to do if your numbers fall in the middle.
What Is a Pathology Report?
When a pathologist takes a biopsy or surgical sample from a tumor and studies it under a microscope, they write down their findings. That's your pathology report. For GEP-NET patients, this document usually includes your tumor grade, a Ki-67 percentage, how the cells look under the microscope, and sometimes results from immunohistochemistry (IHC) staining - tests that show which proteins sit on the cell surface, including somatostatin receptors.
Not every part of the report matters for PRRT eligibility. The items below are what a nuclear-medicine or theranostics team will look at first.
What Ki-67 Actually Measures
Ki-67 is a protein found only in cells that are actively dividing. Pathologists apply a stain to the tumor tissue to show which cells have this protein. They then count how many tumor cells stain positive out of a sample. The result is a percentage - your Ki-67 index.
A Ki-67 of 2 percent means about 2 in every 100 cells were dividing when the sample was taken. A Ki-67 of 40 percent means 40 in 100 were dividing. Higher numbers usually mean your tumor grows faster.
In neuroendocrine tumors, this number determines your tumor grade. Your grade affects which treatments your team will consider, including whether PRRT makes sense for you.
How the WHO Grading System Works for GEP-NETs
The World Health Organization (WHO) sorts neuroendocrine tumors into three grades based on how fast they grow. Most cancer teams worldwide use this system. Your grade depends on your Ki-67 percentage and a second measure called mitotic count - how many cells are actively dividing in a standard piece of tissue. When the two measures point to different grades, doctors use the higher one.
- Grade 1 (G1): Ki-67 below 3 percent. Slow-growing. G1 NETs often stay stable for months or years and usually have plenty of somatostatin receptors.
- Grade 2 (G2): Ki-67 between 3 and 20 percent. Intermediate growth rate. Many G2 NETs respond well to somatostatin receptor-targeted treatments, including PRRT.
- Grade 3 (G3): Ki-67 above 20 percent. Faster-growing. Within G3, there is an important distinction that directly affects PRRT eligibility - explained in the next section.
Your grade alone doesn't decide your treatment. Where the tumor started (the pancreas, small intestine, stomach, or another site), whether it has spread, and what treatments you've already had all matter too. For more context on how different GEP-NET types work and when PRRT comes into play, see our guide to GEP-NET types and when Lu-177 DOTATATE may be the next step.
Well-Differentiated vs. Poorly-Differentiated: The Most Critical Line on Your Report
Differentiation shows how closely a tumor cell still looks like the healthy cell it came from.
- Well-differentiated cells still look like neuroendocrine cells under a microscope. Tumors in this group are called NETs - neuroendocrine tumors. They usually grow in order and typically have somatostatin receptors on their surface.
- Poorly-differentiated cells look very different from any normal cell type. Tumors in this group are called NECs - neuroendocrine carcinomas. They usually grow fast and often don't have the surface receptors that PRRT needs.
Lutetium Lu-177 dotatate works by attaching to somatostatin receptors on tumor cells. Well-differentiated NETs usually have enough of these receptors to absorb the therapy well. Poorly-differentiated NECs often don't. This is why differentiation status - sometimes called histology type or morphology on your report - is one of the first things any PRRT team checks.
If your report says "neuroendocrine carcinoma" instead of "neuroendocrine tumor," ask your oncologist what that means for your treatment options. PRRT usually isn't recommended for NEC, and other options may work better for you.
Which Grades Are Most Likely to Qualify for PRRT?
The strongest evidence for lutetium Lu-177 dotatate comes from the NETTER-1 clinical trial, which enrolled patients with well-differentiated Grade 1 or Grade 2 midgut NETs with a Ki-67 index of 20 percent or lower. That trial led to FDA approval of lutetium Lu-177 dotatate (Lutathera) in January 2018 for somatostatin receptor-positive GEP-NETs in adults. When the National Cancer Institute announced the approval, it noted that the approval covered foregut, midgut, and hindgut neuroendocrine tumors - a bigger group than NETTER-1 itself.
In general:
- G1 NETs: Usually eligible for PRRT when imaging confirms somatostatin receptor expression. This group has strong evidence for PRRT success.
- G2 NETs: Also often eligible, especially when the Ki-67 is clearly below 20 percent. Many G2 patients move to PRRT after their condition gets worse on somatostatin analogue therapy.
- G3 well-differentiated NETs: A different kind of group. These tumors still look like NET cells under the microscope but divide faster than typical G2. Research shows some patients in this group had good results with lutetium Lu-177 dotatate, though outcomes varied and more research is needed.
- Poorly-differentiated NECs: Usually not good for PRRT, no matter what your Ki-67 is. Talk to your doctor about other options.
If your Ki-67 is above 20 percent, the key question isn't just whether you qualify - it's whether your tumor is a well-differentiated G3 NET or a poorly-differentiated NEC. The answer points to very different next steps.
The Role of Somatostatin Receptor Expression
Your pathology report may show IHC results for somatostatin receptor subtype 2 (SSTR2). A strong positive staining result is a good sign - it shows your tumor cells have the receptors that PRRT targets. But IHC staining alone doesn't prove you're eligible for PRRT.
The proof comes from a Ga-68 DOTATATE PET/CT scan. This whole-body imaging scan shows which tumors absorb a somatostatin-targeting tracer and how much. Clinicians use a scoring system to measure uptake across your disease sites, and only patients with strong enough uptake usually qualify for PRRT. According to a clinical overview published in the NCBI Bookshelf, somatostatin receptor positivity on functional imaging is a core requirement for patient selection.
This is why your team looks at both pathology grade and PET imaging together, not separately. A G1 NET with weak receptor uptake on PET usually won't get PRRT, while a G2 NET with strong uptake almost certainly will. For details on how this scan matters for your decision, see our article on how Ga-68 DOTATATE PET determines your PRRT eligibility.
What Else a PRRT Team Looks for on Your Report
Beyond grade and differentiation, a nuclear-medicine team will look at several other things in your pathology report.
- Mitotic count: How many dividing cells appear in a standard piece of tissue. Used with Ki-67 to confirm your grade - the higher number determines your final grade.
- Chromogranin A and synaptophysin staining: These markers prove the tumor is neuroendocrine. Most NETs show positive results for one or both.
- Primary site: Where the tumor started - the pancreas, small intestine, stomach, rectum, or another location. The starting location affects how the tumor behaves and which treatment order doctors recommend.
- Functional status: Whether the tumor releases hormones that cause symptoms like flushing or diarrhea. Functional NETs may need symptom management along with PRRT, but this doesn't keep you from getting treatment.
What If Your Pathology Report Is Old or From a Different Site?
Neuroendocrine tumors can change over time. A biopsy from several years ago might show different results than today. Some NETs develop higher Ki-67 values as they grow or after certain treatments - a process sometimes called grade evolution or grading shift.
If your most recent biopsy is from several years ago, especially if it's before a clear period of growth, your oncologist may suggest a new biopsy from an active or growing lesion. This gives the PRRT team the most accurate picture of how your tumor looks now.
If you had samples taken from different sites - for example, from the original tumor and from a liver metastasis - the grades may be different between locations. In that case, the higher-grade result usually guides treatment planning, and the PRRT team will want to see all samples alongside your imaging.
What to Do If Your Team Is Unsure About Eligibility
If your current oncologist isn't sure whether your pathology grade and receptor status make you a PRRT candidate, a specialist second opinion from a team with deep expertise in theranostics can really help. Theranostics (the combined use of diagnostic imaging and targeted therapy) is a specialized field. Many oncologists aren't experts in PRRT eligibility for borderline cases such as G3 well-differentiated NETs or tumors with mixed IHC results.
You can request a second opinion through Art of Healing Cancer on whether Lu-177 is right for you (and what alternatives exist if not). Their nuclear-medicine team works with GEP-NET patients regularly and can review your pathology grade, receptor expression results, and full treatment history all together.
To learn how lutetium Lu-177 dotatate works at the molecular level before your consultation, see our overview of how lutetium Lu-177 dotatate targets somatostatin receptors.
Questions to Bring to Your Next Appointment
Before your next cancer visit, try to find your most recent pathology report and get answers to these questions if you can:
- What is my Ki-67 index, and what grade (G1, G2, or G3) does that give me?
- Is my tumor well-differentiated (NET) or poorly-differentiated (NEC)?
- Does my report show somatostatin receptor staining results (SSTR2 IHC)?
- How recent is this biopsy, and was it taken from the main tumor or a spread?
- Has my grade changed between biopsies, and if so, what does that mean for my options?
These questions help focus the conversation on PRRT eligibility and help your team explain where you stand. You can also send your pathology report and any imaging results through the Lutetium Therapy contact form for a review. If lutetium Lu-177 dotatate isn't right for you based on your results, the team can also talk about other options worth trying with your oncologist.
When to Talk to Your Doctor
If you have a GEP-NET and haven't heard about PRRT, or if you're unsure whether your pathology grade affects your eligibility, bring it up directly at your next appointment. Ask specifically about your Ki-67 index, your differentiation status, and whether a Ga-68 DOTATATE PET/CT scan is scheduled. If your tumor has gotten worse since your last biopsy, ask whether a new tissue sample would change your treatment options.
This article is for general information and doesn't replace medical advice. Always talk to your oncologist or care team about your specific situation.
Frequently asked questions
What Ki-67 number makes me eligible for PRRT?
The NETTER-1 trial - which formed the basis for FDA approval of lutetium Lu-177 dotatate - enrolled patients with a Ki-67 at or below 20 percent. In practice, Grade 1 (Ki-67 below 3 percent) and Grade 2 (Ki-67 between 3 and 20 percent) well-differentiated NETs are the most commonly eligible groups, provided somatostatin receptor expression is confirmed on Ga-68 DOTATATE PET imaging. There is no single cutoff number that applies universally; eligibility is assessed by combining your Ki-67 result, your histology type, and your PET scan findings.
Can Grade 3 NET patients receive Lu-177 DOTATATE?
It depends on which type of Grade 3 tumor you have. Grade 3 covers two very different categories: well-differentiated G3 NETs and poorly-differentiated neuroendocrine carcinomas (NECs). Well-differentiated G3 NETs - which still look like NET cells under the microscope despite their higher Ki-67 - may retain enough somatostatin receptor expression to show a response to PRRT in some cases, and research in this population is ongoing. Poorly-differentiated NECs are generally not appropriate candidates for PRRT. Asking your oncologist exactly which category your tumor falls into is the most important first step.
What is the difference between a NET and a NEC on a pathology report?
NET stands for neuroendocrine tumor. These are well-differentiated tumors - the cells still resemble normal neuroendocrine cells under a microscope. NEC stands for neuroendocrine carcinoma. These are poorly-differentiated tumors - the cells look very unlike any normal cell type and tend to grow aggressively. The distinction matters because lutetium Lu-177 dotatate depends on somatostatin receptors, which well-differentiated NETs typically express and poorly-differentiated NECs often do not. PRRT is generally designed for NETs, not NECs.
My biopsy is several years old. Do I need a new one before considering PRRT?
Not necessarily, but it is worth discussing with your oncologist. If your disease has progressed or changed behavior since your last biopsy, a more recent sample from an active lesion may give a more accurate picture of your current tumor grade and receptor status. Some NETs develop higher Ki-67 values over time - a process called grade evolution. If your oncologist suspects the tumor has changed, an updated biopsy from a metastatic site can help clarify whether PRRT remains appropriate and guide the final eligibility decision.
Does a positive SSTR2 stain on pathology mean I automatically qualify for PRRT?
A positive SSTR2 result on pathology (immunohistochemistry staining) is an encouraging sign - it suggests the tumor cells carry somatostatin receptors. But pathology staining alone is not sufficient to confirm PRRT eligibility. You also need a Ga-68 DOTATATE PET/CT scan to show that the receptors are expressed at a high enough level across all disease sites, and that the tumor uptake on the scan meets the threshold required for treatment. Pathology staining and PET imaging together give the most complete picture.
Can my NET grade change over time?
Yes. Neuroendocrine tumors can evolve, and some do develop higher Ki-67 values after periods of progression or following certain lines of treatment. This is sometimes called grade evolution or grading shift. It does not happen in every case, but it is more common in longer disease courses. If your original biopsy showed a G1 or G2 tumor but your disease has since become more active, ask your oncologist whether a repeat biopsy from a current lesion might be informative. An accurate, up-to-date grade is important for any treatment decision, including PRRT.
